ENG/中
老虎證券
市场
行情
24/7新闻
产品
Cash Boost账户
期权
A股通
港股
固定票息票据
美股
ETF
基金超市
美国国债
新加坡股
期货
Tiger BOSS Debit Card
老虎钱袋子
功能
经纪人
定投
CPF/SRS 投资
专栏
美股碎股
TigerAI
费用
综合账户
股票与ETF
期权、窝轮与牛熊证
期货
债券
基金超市
Cash Boost
股票与ETF
融资利率
活动
帮助
账户操作
如何开户
开户文件
账户类型
资金与转仓
入金
DDA快捷入金
出金
转入股票
转出股票
货币兑换
产品与交易
可交易产品
订单类型
交易规则
申报
融资融券
保证金与杠杆
风险管理
做空风险
基金超市
基金开户与交易
Cash Boost账户
Cash Boost 账户FAQ
如何开通 Cash Boost 账户
如何用Cash Boost 账户交易
如何绑定CDP证券账户
Tiger Boss Debit Card
常见问题
费用说明
如何充值
如何使用我的Debit card
账单报表
账单报表
股息(分红)
机构
Tiger Fund Management
机构服务
财富及资产管理人
自营交易机构
介绍经纪商
三方服务商
老虎API平台
登入
立即註冊
Toggle
港股
詳情
本頁面由Tiger Trade Technology Pte. Ltd.提供服務
瑞博生物-B
71.100
0.000
手動刷新
成交量:
- -
成交額:
- -
市值:
121.26億
市盈率:
-38.33
高:
71.100
開:
71.100
低:
71.100
收:
71.100
52周最高:
95.800
52周最低:
58.550
股本:
1.71億
香港流通股本:
1.71億
量比:
- -
換手率:
- -
股息:
- -
股息率:
- -
每股收益(LYR):
-1.855
淨資產收益率:
--
總資產收益率:
--
市淨率:
-183.22
市盈率(LYR):
-38.33
市銷率:
59.43
資料載入中...
總覽
公司
新聞資訊
公告
概念
沒有相關數據
資金流向
資金流入:
資金流出:
實時
日
周
月
季度
年
新聞資訊
追求乙肝功能性治癒 !國內 7 家企業進展迅速,最快已 III 期
医麦客
·
02/15
2026年中國生物科技授權交易將迎爆發式增長,有望創歷史新高
新浪财经
·
02/13
近 60 億美元!不到十天兩起小核酸授權出海
医麦客
·
02/13
瑞博生物-B(06938)因悉數行使超額配股權發行474.14萬股
智通财经
·
02/12
{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股,新股,港股,A股等全球金融理财产品。新加坡华人最信赖的在线投资平台,现在加入即享低费用,24/5 无时差炒美股投资理财!","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股,新股,港股,A股等全球金融理财产品。新加坡华人最信赖的在线投资平台,现在加入即享低费用,24/5 无时差炒美股投资理财!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/hant/stock/06938"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"06938","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"06938\",,,,,undefined,":{"symbol":"06938","market":"HK","secType":"STK","nameCN":"瑞博生物-B","latestPrice":71.1,"timestamp":1771549212104,"preClose":71.1,"halted":0,"volume":0,"delay":0,"changeRate":0,"floatShares":170554910,"shares":170554910,"eps":-1.855,"marketStatus":"開市前","change":0,"latestTime":"02-20 09:00:41","open":71.1,"high":71.1,"low":71.1,"amount":0,"amplitude":0,"askPrice":79,"askSize":200,"bidPrice":69,"bidSize":2000,"shortable":0,"etf":0,"ttmEps":-1.502,"tradingStatus":1,"nextMarketStatus":{"tag":"開盤","tradingStatus":2,"beginTime":1771551000000},"marketStatusCode":1,"adr":0,"listingDate":1767888000000,"exchange":"SEHK","adjPreClose":71.1,"openAndCloseTimeList":[[1771551000000,1771560000000],[1771563600000,1771574400000]],"volumeRatio":0,"lotSize":200,"spreadScale":0,"tradeCurrency":"HKD"},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"06938\",,,,,undefined,":{"symbol":"06938","floatShares":170554910,"roa":"--","roe":"--","lyrEps":-1.855,"shares":170554910,"dividePrice":0,"high":71.1,"amplitude":0,"preClose":71.1,"low":71.1,"week52Low":58.55,"pbRate":"-183.22","psRate":"59.43","week52High":95.8,"institutionHeld":0,"latestPrice":71.1,"committee":0.818182,"eps":-1.855,"divideRate":0,"volume":0,"delay":0,"ttmEps":-1.502,"open":71.1,"prevYearClose":57.97,"fiveDayClose":69,"twentyDayClose":75,"sixtyDayClose":57.97},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/06938\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"06938\",market:\"HK\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"06938\",market:\"HK\",delay:false,,,undefined,":{},"@#url:\"https://hq.skytigris.cn/hkstock/value_analysis/stock/06938\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"06938","date":"2026-02-16","current":-47.336884,"percent":0.5,"low":-50.513246,"twenty":-49.730886,"median":-48.557346,"eighty":-48.093725,"high":-47.784644,"avg":-48.951745,"sd":1.148326,"marketCap":12126454101},"quantilePoints":[{"date":"2026-02-13","current":-47.784644,"twenty":-49.967526,"median":-49.148945,"eighty":-48.330365,"marketCap":11947371445},{"date":"2026-02-16","current":-48.557346,"twenty":-49.730886,"median":-48.557346,"eighty":-48.093725,"marketCap":12126454101}],"updateTime":1771534640464},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"06938\",pageSize:4,pageCount:1,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2611140454","title":"追求乙肝功能性治癒 !國內 7 家企業進展迅速,最快已 III 期","url":"https://stock-news.laohu8.com/highlight/detail?id=2611140454","media":"医麦客","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2611140454?lang=zh_tw&edition=fundamental","pubTime":"2026-02-15 07:20","pubTimestamp":1771111229,"startTime":"0","endTime":"0","summary":"当下,追求功能性治愈已成为全球慢性乙肝治疗领域的核心趋势,国内创新药企也紧跟这一方向积极布局,以 ASO 和 siRNA 为主,还包含了细胞疗法、治疗性疫苗等。同月,AHB-137 的 III 期 AUSHINE 临床研究已顺利完成患者入组。2025 年 9 月,该产品被 CDE 纳入拟突破性治疗品种公示名单。另外,腾盛博药将在 2026 年公布两项额外的 IIb 期研究数据。2025 年 9 月,BW-20507 已经完成 II 期临床试验首例患者给药。其 II 期临床试验已经获得批准。目前,正大天晴正在开展 TQA3038 的 Ib/IIa 期临床试验。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260215073412a4a5af8c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260215073412a4a5af8c&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02137","BK1167","01611","BK1612","06938"],"gpt_icon":0},{"id":"2611165746","title":"2026年中國生物科技授權交易將迎爆發式增長,有望創歷史新高","url":"https://stock-news.laohu8.com/highlight/detail?id=2611165746","media":"新浪财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2611165746?lang=zh_tw&edition=fundamental","pubTime":"2026-02-13 17:05","pubTimestamp":1770973500,"startTime":"0","endTime":"0","summary":"全球制药企业在专利到期前纷纷削减成本,正加大力度寻找中国研发的创新候选药物,行业分析师预计,今年相关授权交易规模将飙升至历史新高。2026 年至今已宣布38 笔对外授权交易;2025 年全年为186 笔。行业咨询机构 Vision Lifesciences 在 2026 年生物科技授权展望中称,中国在抗体药物偶联物领域全球领先,相关授权交易占全球近90%。首付款大幅上涨随着交易规模扩大,全球药企获取中国药物开发权所需支付的首付款也大幅飙升。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260213182820a6f7567b&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260213182820a6f7567b&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["06938","01093","BK1161"],"gpt_icon":0},{"id":"2611165798","title":"近 60 億美元!不到十天兩起小核酸授權出海","url":"https://stock-news.laohu8.com/highlight/detail?id=2611165798","media":"医麦客","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2611165798?lang=zh_tw&edition=fundamental","pubTime":"2026-02-13 07:20","pubTimestamp":1770938451,"startTime":"0","endTime":"0","summary":"根据协议条款,瑞博生物将授予 Madrigal 多款 MASH 领域单靶点及双靶点临床前 siRNA 资产的全球独家研发、生产与商业化权利。Madrigal 的 THR-β 激动剂已经获批上市,用于治疗 MASH,2025 年前三季度销售额 6.4 亿美元,预计全年超过 10 亿美元。这是瑞博生物肝靶向 RiboGalSTAR 平台第二次达成重磅出海合作。早在 2023 年,瑞博生物就此平台与勃林格殷格翰达成共同开发治疗 MASH 的小核酸创新疗法的合作,合作总额超 20 亿美元,成为国内首个向 MNC 许可的 RNAi 技术平台。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026021307240697a5ffdf&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026021307240697a5ffdf&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["06938","BK1161"],"gpt_icon":0},{"id":"2610915655","title":"瑞博生物-B(06938)因悉數行使超額配股權發行474.14萬股","url":"https://stock-news.laohu8.com/highlight/detail?id=2610915655","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610915655?lang=zh_tw&edition=fundamental","pubTime":"2026-02-12 14:11","pubTimestamp":1770876660,"startTime":"0","endTime":"0","summary":"智通财经APP讯,瑞博生物-B(06938)发布公告,于2026年2月10日根据悉数行使超额配股权而发行及配发474.14万股H股股份。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1404580.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","06938"],"gpt_icon":0}],"pageSize":4,"totalPage":20,"pageCount":1,"totalSize":78,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/market/plate/belongs/06938\",params:#limit:6,delay:false,,,undefined,":[]}}